Status:

COMPLETED

Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborating Sponsors:

CTI BioPharma

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

In this trial, we plan to evaluate further the role of arsenic trioxide in the treatment of patients with refractory multiple myeloma. Arsenic trioxide will be used in combination with thalidomide. Al...

Detailed Description

Upon determination of eligibility, patients will be receive: * Arsenic Trioxide + Thalidomide

Eligibility Criteria

Inclusion

  • To be included in this study, you must meet the following criteria:
  • Confirmed diagnosis of multiple Myeloma
  • Received at least one previous chemotherapy regimen at most 3 previous
  • Thalidomide with or without dexamethasone without chemotherapy will not factor in to total number of regimens.
  • Age at least 18 years years
  • Able to perform activities of daily living with minimal assistance
  • Life expectancy more than 3 months
  • Adequate bone marrow, liver and kidney function
  • Must give written informed consent in order to participate.

Exclusion

  • You cannot participate in this study if any of the following apply to you:
  • Women pregnant or lactating.
  • Pre-existing moderate neuropathy
  • Patients with significant underlying cardiac dysfunction
  • Uncontrolled hypercalcemia
  • Active serious infections not controlled by antibiotics
  • History of grand mal seizures (other than infantile febrile seizures)
  • Receiving other medications that prolong the QT interval.
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Key Trial Info

Start Date :

March 1 2002

Trial Type :

INTERVENTIONAL

End Date :

January 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00193544

Start Date

March 1 2002

End Date

January 1 2009

Last Update

January 23 2009

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.